April 9 Quick Takes: BMS tops off CAR T patent win; plus approval for Braftovi plus Erbitux, Merck, BMS, Liquidia, Circassia-AZ, Bridge
Award swells to $1.2B, plus royalties, in Kite CAR T suit
Bristol Myers Squibb Co. (NYSE:BMY) and Memorial Sloan Kettering Cancer Center will receive at least $1.2 billion from Gilead Sciences Inc. (NASDAQ:GILD) after a federal judge awarded the pair an additional $420 million. In December, a jury in the U.S. District Court for the Central District of California found that Yescarta axicabtagene ciloleucel from the Kite Pharma Inc. unit of Gilead willfully infringes on a patent licensed to BMS’s Juno Therapeutics Inc. unit. The additional interest and damages are on top of the $778.3 million BMS and MSKCC were allotted based on the verdict; they will also receive royalties of 27.6% on Yescarta until the patent expires on Aug. 28. 2024.
FDA approves Braftovi combo for colorectal cancer
Pfizer Inc. (NYSE:PFE) said FDA approved BRAF inhibitor Braftovi encorafenib plus Erbitux cetuximab to treat BRAF V600E-mutant metastatic colorectal cancer in a second-line setting. The doublet is also under review by EMA. ...